Phaseline

Companies › Alcamena Stem Cell Therapeutics

Alcamena Stem Cell Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASCT-83
23-amino acid macrocyclic peptide
–Phase 1Neuropathic PainDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07363395ASCT-83Phase 1Neuropathic PainNeurologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.